Anne-Marie Zeeman

Anne-Marie Zeeman

Auto-generated profile, based on publicly available information

Anne-Marie Zeeman


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2017 in eLife
Verified
Journal Article
Open access
AWAnnemarie Voorberg - van der Wel
Annemarie Voorberg - van der Wel
GRGuglielmo Roma
Guglielmo Roma
DGDevendra Gupta
Devendra Gupta
SSSven Schuierer
Sven Schuierer
FNFlorian Nigsch
Florian Nigsch
TDThierry Tidiane Diagana
Thierry Tidiane Diagana
Plasmodium liver hypnozoites, which cause disease relapse, are widely considered to be the last barrier towards malaria eradication. The biology of this quiescent form of the parasite is poorly understood which hinders drug discovery. We report a comparative transcriptomic dataset of replicating liver schizonts and dormant hypnozoites of the relapsing parasite Plasmodium cynomolgi. Hypnozoites express only 34% of Plasmodium physiological pathways, while 91% are expressed in replicating schizonts. Few known malaria drug targets are expressed in quiescent parasites, but pathways involved in microbial dormancy, maintenance of genome integrity and ATP homeostasis were robustly expressed. Several transcripts encoding heavy metal transporters were expressed in hypnozoites and the copper chelator neocuproine was cidal to all liver stage parasites. This transcriptomic dataset is a valuable resource for the discovery of vaccines and effective treatments to combat vivax malaria.

27 December 2018 in eLife
Verified
Journal Article
Open access
NBNicole L Bertschi
Nicole L Bertschi
AWAnnemarie Voorberg - van der Wel
Annemarie Voorberg - van der Wel
AZAnne-Marie Zeeman
Anne-Marie Zeeman
SSSven Schuierer
Sven Schuierer
FNFlorian Nigsch
Florian Nigsch
GRGuglielmo Roma
Guglielmo Roma
Relapses of Plasmodium dormant liver hypnozoites compromise malaria eradication efforts. New radical cure drugs are urgently needed, yet the vast gap in knowledge of hypnozoite biology impedes drug discovery. We previously unraveled the transcriptome of 6 to 7 day-old P. cynomolgi liver stages, highlighting pathways associated with hypnozoite dormancy (Voorberg-van der Wel et al., 2017). We now extend these findings by transcriptome profiling of 9 to 10 day-old liver stage parasites, thus revealing for the first time the maturation of the dormant stage over time. Although progression of dormancy leads to a 10-fold decrease in transcription and expression of only 840 genes, including genes associated with housekeeping functions, we show that pathways involved in quiescence, energy metabolism and maintenance of genome integrity remain the prevalent pathways active in mature hypnozoites.

21 September 2023 in ChemMedChem
Verified
Journal Article
Closed access
Ilaria D'AgostinoIlaria D'Agostino
Ilaria D'Agostino
SZSusi Zara
Susi Zara
Simone CarradoriSimone Carradori
Simone Carradori
VLViviana De Luca
Viviana De Luca
Clemente CapassoClemente Capasso
Clemente Capasso
Claudiu SupuranClaudiu Supuran
Claudiu Supuran

29 January 2021 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
AWAnnemarie Voorberg-Van der Wel
Annemarie Voorberg-Van der Wel
CKClemens H. M. Kocken
Clemens H. M. Kocken
AZAnne-Marie Zeeman
Anne-Marie Zeeman
Recent studies of liver stage malaria parasite-host interactions have provided exciting new insights on the cross-talk between parasite and its mammalian (predominantly rodent) host. We review the latest state of the art and and zoom in on new technologies that will provide the tools necessary to investigate host-parasite interactions of relapsing parasites. Interactions between hypnozoites and hepatocytes are particularly interesting because the parasite can remain in a quiescent state for prolonged periods of time and triggers for reactivation have not been irrefutably identified. If we learn more about the cross-talk between hypnozoite and host we may be able to identify factors that encourage waking up these dormant parasite reservoirs and help to achieve the total eradication of malaria.

15 February 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
NANadia Amanzougaghene
Nadia Amanzougaghene
STShahin Tajeri
Shahin Tajeri
JFJean-François Franetich
Jean-François Franetich
KAKutub Ashraf
Kutub Ashraf
VSValérie Soulard
Valérie Soulard
MDmazier dominique
mazier dominique
The control and elimination of malaria caused by Plasmodium vivax is hampered by the threat of relapsed infection resulting from the activation of dormant hepatic hypnozoites. Currently, only the 8-aminoquinolines, primaquine and tafenoquine, have been approved for the elimination of hypnozoites, although their use is hampered by potential toxicity. Therefore, an alternative radical curative drug that safely eliminates hypnozoites is a pressing need. This study assessed the potential hypnozoiticidal activity of the antibiotic azithromycin, which is thought to exert antimalarial activity by inhibiting prokaryote-like ribosomal translation within the apicoplast, an indispensable organelle. The results show that azithromycin inhibited apicoplast development during liver-stage schizogony in P. vivax and Plasmodium cynomolgi, leading to impaired parasite maturation. More importantly, this study found that azithromycin is likely to impair the hypnozoite's apicoplast, resulting in the loss of this organelle. Subsequently, using a recently developed long-term hepatocyte culture system, this study found that this loss likely induces a delay in the hypnozoite activation rate, and that those parasites that do proceed to schizogony display liver-stage arrest prior to differentiating into hepatic merozoites, thus potentially preventing relapse. Overall, this work provides evidence for the potential use of azithromycin for the radical cure of relapsing malaria, and identifies apicoplast functions as potential drug targets in quiescent hypnozoites.

22 August 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
AWAnnemarie Voorberg - van der Wel
Annemarie Voorberg - van der Wel
AZAnne-Marie Zeeman
Anne-Marie Zeeman
CKClemens H. M. Kocken
Clemens H. M. Kocken
Plasmodium vivax causes the second highest number of malaria morbidity and mortality cases in humans. Several biological traits of this parasite species, including the formation of dormant stages (hypnozoites) that persist inside the liver for prolonged periods of time, present an obstacle for intervention measures and create a barrier for the elimination of malaria. Research into the biology of hypnozoites requires efficient systems for parasite transmission, liver stage cultivation and genetic modification. However, P. vivax research is hampered by the lack of an in vitro blood stage culture system, rendering it reliant on in vivo-derived, mainly patient, material for transmission and liver stage culture. This has also resulted in limited capability for genetic modification, creating a bottleneck in investigations into the mechanisms underlying the persistence of the parasite inside the liver. This bottleneck can be overcome through optimal use of the closely related and experimentally more amenable nonhuman primate (NHP) parasite, Plasmodium cynomolgi, as a model system. In this review, we discuss the genetic modification tools and liver stage cultivation platforms available for studying P. vivax persistent stages and highlight how their combined use may advance our understanding of hypnozoite biology.